Bolt Biotherapeutics (BOLT) Common Equity (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Common Equity of $19.8 million for Q1 2026, down 25.21% sequentially from $26.5 million in Q4 2025, and down 57.65% YoY from $46.8 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Common Equity (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Common Equity for 7 years, with the latest figure at $19.8 million in Q1 2026.
- Quarterly Common Equity fell 57.65% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.8 million (down 57.65% YoY) and the FY2025 annual result came in at $26.5 million, down 53.66% from the prior year.
- Common Equity eased to $19.8 million in Q1 2026 per BOLT's latest filing, from $26.5 million in the prior quarter.
- Over five years, Common Equity peaked at $228.4 million in Q1 2022 and troughed at $19.8 million in Q1 2026.
- A 5-year average of $107.1 million and a median of $104.2 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2026: Common Equity retreated 24.68% in 2022, then tumbled 57.65% in 2026.
- Over 5 years, Common Equity stood at $171.5 million in 2022, then plunged by 34.26% to $112.7 million in 2023, then plunged by 49.27% to $57.2 million in 2024, then sank by 53.66% to $26.5 million in 2025, then declined by 25.21% to $19.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $19.8 million, $26.5 million, and $32.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | Bolt Biotherapeutics | 5.80 Mn | 5.80 Mn | - | 12.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.64 Mn |
| Mar 31, 2026 | 19.82 Mn |
| Dec 31, 2025 | 26.51 Mn |
| Sep 30, 2025 | 32.10 Mn |
| Jun 30, 2025 | 38.84 Mn |
| Mar 31, 2025 | 46.81 Mn |
| Dec 31, 2024 | 57.20 Mn |
| Sep 30, 2024 | 72.03 Mn |
| Jun 30, 2024 | 85.86 Mn |
| Mar 31, 2024 | 104.16 Mn |
| Dec 31, 2023 | 112.74 Mn |
| Sep 30, 2023 | 128.26 Mn |
| Jun 30, 2023 | 142.13 Mn |
| Mar 31, 2023 | 157.69 Mn |
| Dec 31, 2022 | 171.51 Mn |
| Sep 30, 2022 | 188.45 Mn |
| Jun 30, 2022 | 207.97 Mn |
| Mar 31, 2022 | 228.39 Mn |
| Dec 31, 2021 | 250.12 Mn |
| Sep 30, 2021 | 274.91 Mn |